The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Oxyargin 30 mg/15 mg prolonged release tablets

30 mg/ 15 milligram(s) Prolonged-release tablet

McDermott Laboratories Ltd t/a Gerard LaboratoriesPA0577/220/004

Main Information

Trade NameOxyargin 30 mg/15 mg prolonged release tablets
Active SubstancesOXYCODONE HYDROCHLORIDE
Naloxone hydrochloride dihydrate
Strength30 mg/ 15 milligram(s)
Dosage FormProlonged-release tablet
Licence HolderMcDermott Laboratories Ltd t/a Gerard Laboratories
Licence NumberPA0577/220/004

Group Information

ATC CodeN02AA Natural opium alkaloids
N02AA55 oxycodone, combinations

Status

Authorised/WithdrawnAuthorised
Licence Issued17/11/2017
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletNo document available
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0102-158-024
Interchangeable List DocumentPDF of Interchangeable List
« Back